SARS-CoV-2 und das antivirale Interferonsystem (SARS2_IFN) [Google Tranlate: SARS-CoV-2 and the antiviral interferon system (SARS2_IFN)]
- Funded by Bundesministerium für Bildung und Forschung [German Federal Ministry of Education and Research] (BMBF)
- Total publications:1 publications
Grant number: 01KI20158
Grant search
Key facts
Disease
COVID-19Start & end year
20212021Known Financial Commitments (USD)
$57,052.89Funder
Bundesministerium für Bildung und Forschung [German Federal Ministry of Education and Research] (BMBF)Principal Investigator
Prof. Friedemann WeberResearch Location
GermanyLead Research Institution
Justus-Liebig-Universität GießenResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Pathogen morphology, shedding & natural history
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
Type I interferons (IFN-alpha / beta) and other cytokines represent the first line of defense against viral infections. IFN activates the expression of more than 300 so-called ISGs (IFN-stimulated genes), some of which are able to deliver viruses directly inhibit. Pathogenic viruses often prevent the induction of IFN, block the signaling triggered by IFN or specifically inactivate individual ISGs. They can also trigger the induction of pro-inflammatory cytokines. The quality and strength of IFN and cytokine induction, IFN evasion, and IFS sensitivity, collectively known as the Innate Immunity phenotype, is an important marker of virulence. The aim of our subproject is to establish systems for the detection of the Innate Immunity phenotype of pre-pandemic respiratory viruses in order to be able to carry out a rapid risk assessment. For this purpose, we will measure the activation of cytokines (including IFN) and antiviral ISGs and create an IFN sensitivity profile for each virus examined. In addition, we will generate a library of ISG-expressing cell lines in order to identify specific ISG resistances and sensitivities. The now largely established systems are now to be applied to the new SARS-CoV-2.
Publicationslinked via Europe PMC
Last Updated:5 days ago
View all publications at Europe PMC